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ABSTRACT
Dietary factors, probiotic agents, aging and antibiotics/medicines impact on gut 
microbiome composition leading to disturbances in localised microbial populations. The 
impact can be profound and underlies a plethora of human disorders, including the 
focus of this review; cancer. Compromised microbiome populations can alter bile acid 
signalling and produce distinct pathophysiological bile acid profiles. These in turn have 
been associated with cancer development and progression. Exposure to high levels of 
bile acids, combined with localised molecular/genome instability leads to the acquisition 
of bile mediated neoplastic alterations, generating apoptotic resistant proliferation 
phenotypes. However, in recent years, several studies have emerged advocating the 
therapeutic benefits of bile acid signalling in suppressing molecular and phenotypic 
hallmarks of cancer progression. These studies suggest that in some instances, bile 
acids may reduce cancer phenotypic effects, thereby limiting metastatic potential. In 
this review, we contextualise the current state of the art to propose that the bile acid/
gut microbiome axis can influence cancer progression to the extent that classical in vitro 
cancer hallmarks of malignancy (cell invasion, cell migration, clonogenicity, and cell 
adhesion) are significantly reduced. We readily acknowledge the existence of a bile acid/
gut microbiome axis in cancer initiation, however, in light of recent advances, we focus 
exclusively on the role of bile acids as potentially beneficial molecules in suppressing 
cancer progression. Finally, we theorise that suppressing aggressive malignant 
phenotypes through bile acid/gut microbiome axis modulation could uncover new and 
innovative disease management strategies for managing cancers in vulnerable cohorts.
INTRODUCTION
In the 1940s, bile acids were shown to be inducers 
of cancer in rodents subcutaneously injected with the 
secondary bile acid, deoxycholate (DCA) [1]. This 
generated malignant spindle-celled tumours, indicative 
of epitheliomas (benign growths or malignant carcinomas 
that are classified according to the epithelial cell of origin). 
These early observations were correlatively affirmed 
in epidemiological studies that showed associations 
between bile acids and cancer, notably colorectal cancer 
(summarised in [2]). Since then, extensive research has 
revealed that bile acids act as tumour promoters in a 
variety of organs such as the oesophagus, the liver and the 
stomach lining [3, 4].
However, in recent years, several reports have 
emerged demonstrating the effectiveness of bile acids 
in reducing cell proliferation and migration of some 
cancer cell types. These observations have expanded 
our knowledge base in the understanding of bile acid 
signalling in the aetiology and evolution of cancer. 
However, we must also consider new and significant 
developments that have shaped our understanding of bile 
acid metabolism, namely the microbiome. Through the 
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exploration of contemporary developments in this area, we 
can begin to redefine the bile acid/microbiome axis and its 
putative role in tumour suppression.
Bile acids as emerging molecules in tumour 
suppression
Bile acids are key signalling molecules that 
play important roles as emulsifiers in digestion and 
the absorption of dietary lipids [2, 5–7]. The evidence 
implicating bile acids in cancer (oesophageal, stomach, 
gut) has been extensively documented throughout the 
literature [3, 8, 9]. A combination of mechanisms appears 
to be responsible for bile induced cancer in organs where 
elevated bile acid levels persist, e.g. oxidative damage 
(ROS), epithelium proliferation, cell death, signalling 
activation and localised DNA instability [6]. Specifically, 
at the colon, bile acid induced mitochondrial dysfunction 
leads to oxidative damage, ROS accumulation and localised 
cell membrane damage [10, 11]. Similarly, DCA has been 
shown to induce epithelium hyper-proliferation via the 
activation of epidermal growth factor receptor (EGFR), 
extracellular signal-regulated kinase (ERK) and protein 
kinase C (PKC) signalling pathways [11]. Prolonged 
exposure to bile acids at the colon can also increase 
apoptosis and apoptosis resistance, via mitochondrial 
stress and ROS release, activation of cytochrome C and 
members of the Bcl-2 family [11, 12]. These mechanisms, 
and others (e.g. mitosis disruption, G1/G2 cell cycle arrest, 
endoplasmic stress) lead to chromosomal instability and 
DNA damage, underpinning the initial stages of colorectal 
tumorigenesis, thereby aggravating an already unstable 
environment [2, 6, 11, 13, 14, 15, 16].
The macro-level damage described above is 
also associated with significant changes in several key 
signalling pathways (Table 1). Constitutive activation 
and translocation of the transcription factor NF-κB, a 
protein involved in DNA transcription, inflammatory 
cytokine production and enhanced cell survival, occurs in 
response to DCA exposure at the oesophagus and colon 
[6, 14, 17–19]. Similarly, expression of cyclooxygenase, 
COX2 and prostaglandin E2 (PGE2) (a member of the 
prostaglandin family involved in inflammation, cell 
growth and hormone regulation) is significantly elevated 
in pancreatic cancer cell lines (BxPC-3 and SU 86.86) 
in response to DCA and CDCA [20]. COX2, cited as a 
stress marker induced in Barret’s mucosa (a predictor of 
oesophageal adenocarcinoma), is increased upon exposure 
to DCA and chenodeoxycholate (CDCA) in squamous 
cancer oesophageal cells. Interestingly, in the same study, 
a key regulator of squamous regulation p63, was rapidly 
decreased upon exposure to DCA, suggesting p63 could 
be lost in the transition between squamous and metaplasia 
phenotypes when exposed to bile acids [21].
Notwithstanding these observations, it has been 
shown that key in vitro cell morphological characteristics 
of cancer cells (e.g. cell invasion, cell migration, cell 
adhesion and cell survival) can be targeted by bile acids to 
suppress metastatic phenotypes in several cancer models 
(Table 2). In the leukaemia cell line HL60, DCA, CDCA 
and lithocholic acid (LCA) inhibit cell proliferation and 
induce cell differentiation with a mechanism implicating 
protein kinase C (PKC) [23]. Similarly, in HL60 cells 
and the leukaemia cell line THP-1, bile acids induce a 
positive cooperativity with retinoic acid and vitamin D in 
promoting differentiation, and down-regulating the serine 
protease myeloblastin. The expression of myeloblastin is 
associated with the promotion of cellular differentiation 
in myeloid leukaemia [22–24]. The proliferative capacity 
of the pancreatic cell lines, PANC-1, MIA PaCa-2 and 
PGHAM-1 have been tested in response to DCA. Cell 
proliferation was reduced and structural alterations to 
microvilli were observed in some cell lines, suggesting 
DCA could limit in vitro pancreatic cancer cell progression 
and invasion [25]. DCA and CDCA destabilised the 
transcription factor, Hypoxia Inducible Factor-1α (HIF-
1α) in the immortalised bronchial epithelial cell line 
IB3-1 derived from a cystic fibrosis (CF) patient [26]. 
Similarly, DCA was shown to inhibit cell invasion, cell 
migration and cell proliferation in the gastric carcinoma 
cell lines SNU-216 and MKN45 [27]. This was 
accompanied by simultaneous reductions in Snail and 
MMP9 expression, proteins which are associated with 
aggressive menenchymal cell phenotypes. Similarly, 
increases in MUC2 and E-cadherin expression were 
also recorded and are associated with less aggressive 
cancers. Critically, these observations were used in a 
retrospective study to clinically evaluate tumour samples 
from a cohort with good cancer prognoses. MUC2 positive 
tumours showed reduced Snail expression, suggesting bile 
acids could regulate tumour behaviour in oesophageal 
and colon cancers [27]. The most recent study by our 
group, investigated the effects of DCA and CDCA in 
hypoxia induced prostate and breast cancer models, 
where HIF-1α was constitutively activated. We observed 
significant reductions in cell invasion, cell migration, 
cell adhesion and cell survival (clonogenicity) in the 
presence of physiological levels of bile acids, without 
inducing cytotoxicity or apoptosis [28]. Concomitantly, 
we observed that HIF-1α was significantly destabilised 
(when compared to controls) and the expression of its 
downstream signalling effector hexokinase II (HKII) was 
also reduced.
These studies exemplify an increasing awareness 
of the suppressive effects (molecular and phenotypic) 
of bile acids in the evolution of some cancers. However, 
defining the roles of these molecules in cancer is not 
helped by complicated bile acid receptor expression 
profiles and signalling mechanisms at the nucleus and 
plasma membrane. In their comprehensive review, 
Baptissart et al., proposed that bile acids may have 
paradoxical functions depending on tissue distribution 
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and the relevant bile acid receptor [29]. For example, 
farnesoid X receptor (FXR) expression at the oesophagus 
may promote inflammation and apoptosis resistance, 
while opposite effects may be exerted in the liver and 
intestine. Equally, it has been shown that different bile 
acids (conjugated and unconjugated) can exert differential 
FXR expression in a cholangiocarcinoma cell model 
[30]. Notwithstanding this complex receptor biology, it 
has been proposed that high levels of FXR expression 
could be strong positive prognostic indicators in invasive 
breast cancer [31]. Similarly, high TGR5 expression may 
be associated with oesophageal adenocarcinoma but may 
have more complex functions in the liver and intestine 
[29]. Strategies to target specific receptors in specific 
organ types must be informed by the knowledge that these 
receptors are required for normal physiology e.g. FXR and 
its role in bile acid/cholesterol homeostasis in the liver 
[32]. However, potential therapeutic advances have been 
made in this area, e.g. the identification of a detoxifying 
role for FXR in colorectal cancer (CRC), the third most 
common malignancy worldwide [11].
Factors shaping bile acid profiles
The bile acid/microbiome axis
While the molecular and cell behavioural events 
induced by bile acids in cancer development are important, 
it is vital to assess factors that shape and sculpt bile acid 
profiles. The role of intestinal microbiota-derived bile 
acid metabolites in the aetiology of colorectal cancer was 
hypothesised several decade ago [33, 34]. Understanding 
and dissecting the microbiome/bile acid axis will help 
identify how potentially pathophysiological bile acid 
profiles are generated in the body and more importantly, 
how they impact on cancer development.
The gut microbiome is a community of commensal, 
symbiotic and pathogenic microorganisms that inhabit the 
gastrointestinal tract contributing both to human health 
and disease. Dietary and environmental factors, lifestyle 
choices or other conditions that impact on the composition 
and metabolic activity of intestinal microbiota, can lead 
to dramatic alterations in bile acid pools which in turn 
affects host metabolism and homeostasis [35–38]. The 
gut microbiota regulate bile acid metabolism, including 
the synthesis, conjugation, uptake and recirculation to 
the liver via the portal vein through FXR modulation, as 
well as by the transformation of bile salts into secondary 
bile acids [39]. Activation of bile-responsive receptors 
are not only key for bile acid metabolism, but they also 
influence a host of metabolic processes including, glucose 
homeostasis, lipid and lipoprotein metabolism, energy 
expenditure, intestinal bacterial growth, inflammation, 
liver functions, and hepato-carcinogenesis [40]. On the 
other hand, bile acids can also configure the structure 
of intestinal bacterial communities by selecting bile 
tolerant microbes or by fitness gain conferred by specific 
bile acid profiles [41]. The picture becomes even more 
complicated when we consider additional components 
of the gut ecosystem such as the enteric bacteriophage 
community, which has been poorly characterised and 
may participate in gut response to bile acids. The enteric 
virome regulates gut microbial population dynamics 
contributing to the normal functioning and resilience of 
the gut community [42]. Differential bile acid tolerances 
have been reported for some bacteriophages [43, 44], 
suggesting that bile acid-mediated modulation of enteric 
bacteria could be secondary to changes in bacteriophage 
diversity. Accordingly, recent studies have shown that 
the distinctive compositional signatures of gut bacteria 
linked to different human conditions are associated with 
specific enteric viromes [42]. Thus, different host-derived 
bile acid profiles may also alter bacterial composition and 
the production of secondary bile acids, by selecting for 
singular phage populations.
The gut microbiota also regulates inflammatory 
responses in the host by controlling the production of 
specific secondary bile acids such as LCA (lithocholic 
acid) or DCA, which activate the bile-responsive receptors 
FXR and TGR5. Activation of FXR or TGR5 results in 
an anti-inflammatory response by supressing the NF-
kB-mediated production of pro-inflammatory cytokines 
in immune cells and the Caco-2 intestinal epithelial 
cell line [45, 46]. Accordingly, the dysregulation of bile 
acids has been implicated in several human diseases 
associated with inflammation, e.g. liver cirrhosis [7, 52], 
inflammatory bowel disease [45, 46, 47] type -2 diabetes 
(T2DM) [53] and cardiovascular disease (CVD) [54, 55]. 
These conditions have been associated with specific gut 
microbiota compositional and/or functional profiles [45, 
56, 57]. This suggests that events at the microbiome 
have far reaching consequences and are not just limited 
to host metabolic disorders [50, 51]. For an in-depth 
and comprehensive review on the role of bile acids in 
metabolic disorders, refer to Jones et al. [5].
What precisely causes these pathological 
manifestations remains to be fully delineated. For cancer, 
bile acid mediated initiation appears to be promoted 
through several factors (individual or combined) (Figure 
1); i) supra-physiological levels of bile acids (DCA) 
linked to poor nutrition, ii) lipid membrane composition 
at susceptible organs [25, 58], iii) ROS-mediated damage 
at epithelium barriers between host and microbiome, 
generating inflammation and hyper-proliferative 
epithelium phenotypes [6], iv) excessive pH fluctuations 
(e.g. due to over reliance on medicines) causing 
resurgences of pathogenic microbial populations [8] and 
v) activation of transcriptional programmes regulated 
by different nuclear receptors and altered production of 
cytokines that induce pro-inflammatory responses [11, 
45, 59]. Unlocking the molecular interplay between these 
factors and their association with elevated bile acids 
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(excessive DCA production) and cancer progression could 
shed light on the altered expression of key biochemical 
messengers, e.g. NF-kB and FXR (Figure 2), that when 
combined not only promote localised epithelium damage 
but also early stages of colorectal cancer [2].
Diet appears to be a pivotal factor in controlling 
bile acids. DCA levels are controlled by the bile salt 
hydrolysing Roseburia and Faecalibacterium to maintain 
BA pool sizes and composition. Fibre rich diets stimulate 
the growth of both Roseburia and Faecalibacterium 
Figure 1: Events initiating bile acid mediated cancer. Supra-physiological levels of bile acids exacerbate key cellular physiological 
events in cancer development.
Table 1: The impact of bile acids on signalling pathways involved in cancer aetiology
Bile Acid Signal Pathway/Molecular basis Bile acids mediated cancer Reference
DCA ROS mediated NF-κB activation Oesophageal Cancer Jenkins et al (2008)
DCA
(plus aspirin) NF-κB activation Gastric apoptosis (limited by aspirin) Redlak MJ et al (2008)
Bile Acids ROS, DNA damage, inflammation, NF-κB activation, enhanced cell proliferation Colon cancer Payne CM et al (2007), Jenkins et al
CA Activates Cdx2 promoter via NF-κB Metaplasia leading to Barrets’ oesophagus Kazumori et al (2006)
CDCA and DCA Targets COX2 (stress responder) and p63 (transcriptional regulator)
Squamous to metaplasia cell 
transition in Oesophageal Cancer Roman S et al (2007)
Bile acids Deregulation of  TSC1/mTOR by bile acids Oesophageal adenocarcinoma Yen et al (2008),
DCA ROS induction, DNA damage (dose dependent) MUC2 induction
Oesophageal Adenocarcinoma and 
DCA
Jenkins GJ et al (2008)
Wu J et al (2008)
DCA
DCA combined with methylselenol inhibits 
colon cancer cell proliferation. Induces SAPK/
JNK1/2, p38 MAPK, ERK1/2 activation
Colon Cancer Zeng et al (2010)
DCA
DCA targets cell proliferation and decreases 
suppressor activation in cell cycle and apoptosis. 
Activates ERK1/2, caspase-3 and PARP
Colon Cancer Zeng et al (2015)
DCA ROS induced genotoxicity in OE33 cells Oesophageal Cancer Jenkins et al (2007)
The major target of bile signalling appears to be NF-κB which is activated in several cancers including colon and oesophageal cancer.
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species as well as promoting bile acid metabolism 
[60, 61]. Deficiencies in these genera can therefore upset 
DCA production and increase inflammation, leading to 
ulcerative colitis, a precursor to colon cancer [45, 62]. 
DCA production can become elevated thanks to high 
fat diets, inhibiting the growth of particular taxa of the 
phyla Bacteroidetes and Firmicutes, causing dysbiosis, 
e.g. inflammatory bowel disease, a potential precursor to 
colorectal cancer [63, 64].
It is a sobering thought that only a small fraction 
of all microbes are easily cultured and characterised in 
the laboratory [65]. Concerted efforts should be made to 
study and characterise microbiome strains that have been 
implicated in cancer. Strains such as Enterobacteriaceae 
that are associated with bile acid fluctuations in liver 
cirrhosis, and bile modulating strains such as Clostridia 
and its reported association with liver cancer development, 
require complete genotyping and characterising to 
delineate their precise roles in vulnerable cancer-
susceptible individuals and cohorts [7, 8]. Significant 
efforts have yet to be made in this area, however Ahern et 
al provide a valuable procedural template in their quest to 
mine microbiota strains implicated in the immune system 
[66]. They suggest approaches including, culturing using 
Figure 2: Molecular events arising in response to (A) bile acid homeostasis and (B) bile acid dysregulation. (A) Unaltered gut microbiota 
enzymatically modify primary bile acid pools (conjugated and unconjugated bile acids) to unconjugated secondary bile acids DCA and 
LCA. Secondary bile acids activate the nuclear receptors FXR, PXR and the G protein-coupled receptor TGR5 preventing NF-kB-mediated 
production of pro-inflammatory cytokines. FXR activation also inhibits bile acid synthesis in the liver and maintenance of bile acid 
homeostasis. LCA can also induce the (Vitamin D-Receptor) VDR and PXR-mediated transcription of genes involved in the detoxification 
and clearance of toxic metabolites such as LCA. (B) Factors affecting gut microbiota can alter the bile acid/gut microbiome axis, generating 
pathophysiological levels of bile acids and bile profiles that no longer activate FXR, PXR, VDR and TGR5, facilitating NF-KB-mediated 
expression of pro-inflammatory cytokines. Production of toxins or harmful metabolic by-products by dysbiotic gut microbiota also stimulate 
production of inflammatory markers by immune cells, which in turn contributes to disruption of the epithelial barrier. Downregulation of 
genes involved in the clearance of harmful metabolites, contributes to the accumulation of hydrophobic secondary bile acids in the intestinal 
lumen, which can induce damage in the cell membrane. The absence of FXR-mediated signalling results in the loss of inhibition of bile 
acid synthesis in the liver, contributing to a vicious cycle that increases levels of bile acids in the intestinal lumen. This exacerbates a pro-
inflammatory phenotype. Together with excessive ROS production and localised genomic instability, preliminary neoplasms develop in 
vulnerable tissues and organs e.g. oesophagus, intestine and colon.
Oncotarget115741www.impactjournals.com/oncotarget
complex media, dysbiotic gut transplantation into germ 
free mice, generation of strain libraries and intensive low 
error amplicon 16sRNA sequencing (LEA-Seq).
The diet
The adoption of busier lifestyles means that 
“healthy” diets are often side-lined, leading to 
compromised eating habits with detrimental effects on 
health [67]. Eschewing healthier options sustains diets 
high in processed sugars, complex carbohydrates and 
saturated fats which complicate disorders such as diabetes, 
obesity and CVD. When seditious lifestyles are included, 
health and socio-economic issues become critical, leading 
to an overweight, chronically unfit population prone to 
deleterious ill health and potentially long term debilitating 
disease [68–71].
Several reviews suggest the consumption of 
red meat and dietary fats may be direct contributory 
factors to the development of cancers at e.g. the 
colon and liver [9, 72, 73]. Similarly, dairy products 
containing bile acid hydrolysing (BSH) genera 
(Lactobacillus and Bifidobacterium) should be carefully 
evaluated in terms of their potential impact on vulnerable 
cancer patients or sur viv ors [74]. BSHs have traditionally 
been identified as effective probiotics in the modulation 
of metabolic disease [5, 62], however BSH metabolism 
could lead to the generation of unwanted unconjugated 
secondary bile acids, exacerbating DNA instability at 
the colon [75]. Restoring normal bile acid profiles could 
be mediated by supplementing diets with probiotics 
(strains from the Lactobacillus and Bifidobacterium 
genera), prebiotics or non-digestible foodstuffs (inulin 
and trans-galacto-oligosaccharides) that would improve 
bile metabolic regulation and help readdress beneficial 
gut fauna [8, 76]. Much speculation exists in the literature 
regarding the use of probiotics and prebiotics against e.g. 
pancreatic, colon and colorectal cancer [77–80]. There is 
some evidence to suggest that secreted metabolites derived 
from Lactobacillus strains reduce the viability of colon 
cancer cells (Caco-2 and HT-29). These metabolites have 
been shown to downregulate the key receptor tyrosine 
kinases, Erb-2 and Erb-3, however the physiological 
implications of these findings have yet to be determined 
[81]. It is evident from the dearth of information in the 
literature that more research is required to fully realise the 
potential of microbial based therapies in restoring bile acid 
homeostasis in cancer cohorts where recurrence of disease 
is common.
While the generation of novel probiotics and 
microbiota-based strategies could potentiate bile signalling 
in cancer progression, there remains the possibility that 
control of bile acids from a dietary perspective could 
decrease susceptibility to cancer. Non-empirical evidence 
suggests that Mediterranean diets (fruits and vegetables, 
whole grains, legumes and nuts, olive oil, herbs and 
spices, limited red meat, fish and poultry and red wine 
(in moderation) could provide “probable” long term 
protective roles against cancer initiation [82]. However, 
while empirical data from a human perspective is not 
available [35, 48], it would be informative to conduct 
well designed and controlled, randomised, longitudinal 
bile acid (supplemented via probiotics or diet) studies 
in cohorts that are susceptible to colon, oesophageal or 
gastric cancers.
Bile/Microbiome mediated anti-cancer therapies
Targeting and reducing excess bile acids without 
affecting normal signalling should be the main goal 
of research in this area. The advent of high throughput 
next generation sequencing methods targeted at bile acid 
producing bacteria could dramatically improve clinical 
diagnostics in cohorts where microbiome-related issues 
prevail [83]. For example, limited spectrum and non-
absorbable antibiotics (e.g. ampicillin, vancomycin, 
neomycin and metronidazole) could target DCA mediated 
genotoxicity, generated by DCA producing bacteria (e.g. 
Table 2: The potentially therapeutic impact of bile acids on cancer development
Bile Acid Signal Pathway/Molecular basis Bile acid modulated cancer Reference
Lithocholic acid (LCA)
Promotes cleavage of Bid and Bax and down-
regulation of Bcl-2. No effect on prostate cell 
proliferation
Prostate Cancer Goldberg et al (2013),
CDCA and DCA HIF-1α  destabilisation and significant reduction in cancer invasion phenotypes Prostate and Breast Cancer Phelan et al (2016)
CDCA and DCA HIF-1α  destabilisation Metastatic Cancer Legendre et al (2014)
DCA
DCA induction of MUC2 and inhibition of cell 
invasion and migration, reduction in Snail and 
MMP9 expression
Gastric Carcinoma Pyo et al (2015)
Bile acids
Inhibition of HL60 and THP-1 proliferation, 
retinoic acid and vitamin D in differentiation, and 
down-regulating the serine protease myeloblastin
Leukaemia Zimber et al (1994)Zimber et al (2000)
UCDA Derivatives arrested cell cycle at G1, suppressed cdk2 and E-dependent kinase activities, Prostate Carcinoma
Xu et al (2017)
Choi et al (2003)
For some cancers, bile acids appear to suppress cancer invasion phenotypes and may destabilise HIF-1α, a key regulator of hypoxia in metastatic disease.
Oncotarget115742www.impactjournals.com/oncotarget
Costridia) in high risk colon cancer patients [8, 73]. 
Similarly, DCA levels are reduced in mice by decreasing 
7α-dihydroxylation activity using fructose anhydride III 
or increasing bile acid secretion through ursodeoxycholic 
acid (UCDA) administration [84]. UDCA has long been 
speculated to act as a potential therapeutic agent in the 
treatment of colorectal and liver cancer. Chronic UDCA 
enrichment of rodent diets decreased DCA pools and 
decreased the incidence of benign and malignant tumours 
in these animals [2]. Similarly, UCDA and di-fructose 
anhydride III was shown to block DCA production in 
obese mice, preventing hepatocellular carcinoma in 
these animals [73]. UCDA appears to have potentially 
chemotherapeutic effects in humans. In a human phase III 
trial, UDCA administration was associated with significant 
reductions in the recurrence of colorectal adenomas with 
high-grade dysplasia in 1285 patients, a key finding for 
those prone to invasive colorectal carcinoma [85]. The 
generation of a synthetic derivative of CDCA (HS-1200) 
has been shown to be effective in inhibiting proliferation 
of prostate cancer cells, bone sarcoma cells and hepato-
carcinogenesis in rats [86, 87]. Lastly, the use of the 
synthetic acid derivative obeticholic acid, a strong FXR 
agonist has been demonstrated to be a highly effective 
treatment for patients with primary biliary cirrhosis 
[88]. The efficacy of obeticholic acid in patients with 
primary biliary cirrhosis with inadequate responses to 
ursodeoxycholic acid could be a promising therapeutic 
option for treating liver disease.
Equally, microbiome transplantation, traditionally 
used for alleviating Clostridium difficile infections, 
has proven successful for some patients with colitis 
(precursor to cancer). The approach, however should be 
viewed with caution as pathogen and virus transmission 
to new hosts could induce host-specific microbiome 
immune effects [8, 76]. Notwithstanding these difficulties, 
microbiota transplantations appear to have universal 
appeal as therapies in the treatment of disorders such 
as microbiota-brain-gut axis dysregulation, metabolic 
and mood disorders. Therefore, their use as potential 
cancer therapies is a distinct possibility [49]. Similarly, 
future studies on non-bile modulating organisms could 
be used to regulate gut dynamics to protect against bile 
acid producing pathogens implicated in colon cancer. 
In support of this, preliminary research in predisposed 
mice, has shown that a Lactobacillus acidophilus strain 
deficient for lipoteichoic acid (LTA) regresses colonic 
polyps, a precursor to colon cancer [89]. Could genetically 
modified L. acidophilus strains provide protective effects 
against pathophysiological bile acid levels in susceptible 
Figure 3: How bile acids may influence cancer progression. Factors incorporating an unbalanced approach to diet (red line), junk 
food, excessive medicine/probiotic intake and age affect bile acid production. This alters the bile acid/gut microbiome axis, generating 
pathophysiological levels of bile acids. Together with excessive ROS and localised genomic instability, preliminary neoplasms can develop 
in vulnerable tissues and organs e.g. oesophagus, intestine and colon. Conversely, a healthy approach to diet (black line), appropriate 
medicine intake and other factors may help reduce pathophysiological bile levels, thereby maintaining a healthy bile acid/ gut microbiome 
axis. If potentially metastatic lesions are present in susceptible organs, physiological bile acid levels could limit cell invasion, cell migration 
and cell adhesion phenotypes.
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colon cancer cohorts? For liver cancer susceptibility 
in obese cohorts, continuous monitoring of serum and 
faecal DCA levels could prove effective in predicting 
obesity associated liver cancer [90]. Supplementation 
of antioxidant agents to limit DCA-dependent ROS 
cell membrane damage has also been proposed as a 
potential therapy for Barret’s oesophagus patients [14, 
91]. Similarly, aspirin could exert chemo-preventative 
effects on key apoptotic signalling molecules at different 
organ sites; e.g. in human gastric carcinoma cells, aspirin 
prevented DCA induced caspase-3, -6 and -9 activation, 
DNA degradation, poly (ADP-ribose) polymerase 
and lamin A processing [18]. In an oesophageal 
adenocarcinoma cell line, aspirin decreased MUC2 
transcription and NF-κB activity [19]. Whether these pre-
clinical observations can be translated to human studies 
remains to be seen.
CONCLUSIONS AND PERSPECTIVES
The key genomic fault-lines that underpin cancer 
progression; intrinsic DNA/genomic instability, high 
cell turnover and regulation of cell survival/apoptosis/
necrosis are chronically exacerbated by persistent supra-
concentrations of bile acids at e.g. the colon, oesophagus 
and stomach. However, reports have shown that bile acids 
can have therapeutic effects on some cancer cell types, 
eliciting dramatic changes in cancer cell characteristics 
(cell adhesion, cell migration and cell invasion). How 
these effects are elicited remains to be elucidated, but 
it is tempting to speculate that bile signalling may have 
implications for hypoxic metastatic tumour development 
where  HIF-1α is destabilised and expression of its 
effector, hexokinase II (HKII) is decreased [26, 28].
It has been observed that dysbiosis occurs in 
many inflammatory diseases, suggesting that defects in 
inflammatory signalling could contribute to these disease 
states [35]. Bile acids not only target and destabilise 
HIF-1α, but they induce the differential expression of the 
interleukins, IL-6 and IL-8 in airway epithelial cells [92]. 
These findings are important for two reasons. Firstly IL-8 
mRNA expression is increased in colorectal cancer and 
secondly IL-8 mRNA expression is decreased in an airway 
epithelial cell model [92, 93]. It is thus tempting to postulate 
that excessive circulating bile acids induce differential 
inflammatory responses contributing to downstream 
epithelium hyper-proliferation in the colon and oesophagus.
The role of bile acid signalling in cancer progression 
is not a singular event; diet, probiotics, medicine, aging 
and the environment shape the bile acid/microbiome 
axis, therein determining bile acid levels and profiles. 
An unbalanced approach to diet and medicine intake 
may elevate bile acid levels and alter bile acid profiles 
to pathophysiological levels. This contributes to cell 
membrane damage and DNA instability through 
excessive ROS production. Downstream activation 
of important regulatory and inflammatory pathways 
(PKC, NF-κB, EGFR etc.) may lead to or exacerbate 
neoplastic cell proliferation in vulnerable organs e.g. 
oesophagus, stomach and colon (Figure 3). Conversely, 
a healthy balanced approach to diet, medicine intake and 
other factors may contribute to physiological levels of 
circulating bile acids, thus reducing pathophysiological 
bile levels. If a pre-cancerous lesion (with metastatic 
potential) is present in a susceptible organ, physiological 
bile acid levels could, based on the data presented here, 
limit progression of malignant cells (Figure 3).
In conclusion, the bulk of the literature promotes 
an associative relationship between bile acids and some 
cancers reinforcing a “foe” element of bile acids and 
its role in cancer. However, there remains the distinct 
possibility that some bile acids can elicit anti-cancer 
phenotypes (the “friend” element) in cells that have 
already undergone an initial malignant transformation 
(e.g. through HIF-1α activation). The maintenance of 
a balanced bile acid/microbiome axis could limit the 
metastatic potential of some cell types. Characterisation 
of this axis requires high-throughput metagenomics-
sequencing approaches, intensive identification methods 
using the latest 16sRNA technologies, molecular based 
studies and practical, well-conceived human randomised 
trials. These approaches may provide some answers 
to the following questions; i) how do bile receptors in 
different tissues respond to bile acids, ii) what are the 
downstream targets of this regulation and can these bile 
receptors be targeted in those susceptible cancer cohorts 
with a dysfunctional bile acid/microbiome axis profile, iii) 
can harmful bile modulating gut pathogens be replaced 
by beneficial ones? While these questions remain to be 
answered, the solution for most lies in the diet. Promoting 
healthier eating habits could, in the long term, reduce 
predisposition to certain cancers where bile acids are 
perceived as contributory agents to disease.
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